KV jumps 119% on FDA probe of competing compounded preterm birth drug
This article was originally published in Scrip
Executive Summary
Shares of KV Pharmaceuticals shot up as high as 119%, or $1.06, on 8 November after the US FDA revealed that it is testing hydroxyprogesterone caproate products compounded at pharmacies and the bulk active pharmaceutical ingredients (APIs) used to make those products, which are sold at a fraction of the cost of the company's approved drug Makena.